02595.HK
GenFleet Therapeutics (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 27.50
−0.51%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
HKD 9.67B
MomentumView details →
1D Return
−0.51%
YTD Return
+15.45%
RSI (14)
38.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
HKD 9.67B
RSI (14)
38.6
MomentumView details →
1D Return
−0.51%
YTD Return
+15.45%
Similar companies
Latest newsMore news →
GenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has entered a Phase II study as first-line treatment for advanced non-small cell lung cancer with KRAS G12D mutation.10d agoGenFleet Therapeutics (B) reported interim results for the six months ended June 2026, with revenue of RMB 42.47 million, down 52.1% year-on-year, and a narrowed net loss of RMB 220 million versus RMB 699 million a year earlier.15d agoGenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has initiated a registrational Phase III clinical study for non-small cell lung cancer, with the first patient enrolled at Nanjing Drum Tower Hospital.26d ago